These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 3090314)

  • 1. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
    Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of mesna with ifosfamide.
    Goren MP
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C; Steiner R; Viollier AF
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
    Matsumoto S; Kawaguchi N; Manabe J; Kuroda H; Shimoji T
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):965-8. PubMed ID: 7794006
    [No Abstract]   [Full Text] [Related]  

  • 7. Protective effect of ketamine against hemorrhagic cystitis in rats receiving ifosfamide.
    Ozguven AA; Yılmaz O; Taneli F; Ulman C; Vatansever S; Onag A
    Indian J Pharmacol; 2014; 46(2):147-51. PubMed ID: 24741183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
    Frustaci S; Foladore S; De Pascale A; Freschi A; Lo Re G; Sorio R; Errante D; Monfardini S
    Ann Oncol; 1992 Apr; 3 Suppl 2():S115-8. PubMed ID: 1622852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nursing implications in the administration of ifosfamide and mesna.
    Richters JE
    Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.
    Ali SA; Danda SK; Basha SA; Rasheed A; Ahmed O; Ahmed MM
    Indian J Pharmacol; 2014; 46(1):105-8. PubMed ID: 24550594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
    Goren MP; McKenna LM; Goodman TL
    Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z; Utracka-Hutka B
    Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
    [No Abstract]   [Full Text] [Related]  

  • 14. Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
    Dornelas-Filho AF; Pereira VBM; Wong DVT; Nobre LMS; Melo AT; Silva CMS; Wanderley CWS; Nour ML; Araújo LCNC; Silva RO; Pinto FMM; Bingana RD; Souza MHLP; Alencar NMN; Silva PGB; Alves APNN; Almeida PRC; Cunha FQ; Lima-Júnior RCP
    Int Immunopharmacol; 2018 Sep; 62():96-108. PubMed ID: 29990699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W; Klein HO; Brock N; Burkert H; Günther U; Hoefer-Janker H; Mitrenga D; Schnitker J; Voigtmann R
    Cancer Treat Rep; 1979 Mar; 63(3):501-5. PubMed ID: 106965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
    Vieira MM; Brito GA; Belarmino-Filho JN; Macedo FY; Nery EA; Cunha FQ; Ribeiro RA
    Int J Urol; 2003 Nov; 10(11):595-602. PubMed ID: 14633084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
    Saito Y; Kumamoto T; Makino Y; Tamai I; Ogawa C; Terakado H
    Jpn J Clin Oncol; 2016 Sep; 46(9):856-61. PubMed ID: 27380806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide and mesna.
    Med Lett Drugs Ther; 1989 Nov; 31(804):98-9. PubMed ID: 2554100
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE; Tessler J
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ifosfamide-induced urinary bladder lesion and its inhibition by mesna].
    Muraoka Y; Watanabe H; Matsui S; Nara H; Kasai H
    Nihon Yakurigaku Zasshi; 1990 Aug; 96(2):73-83. PubMed ID: 2121633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.